SOUTH EASTON, Massachusetts, June 4, 2020/ PRNewswire/– Pressure BioSciences, Inc. (OTCQB: PBIO) (” PBI” or the “Company”), a leader in the advancement and sale of broadly making it possible for, pressure-based instruments, consumables, and platform technology solutions to the around the world biotechnology, biotherapeutics, cosmeceuticals, nutraceuticals, and food & drink markets, today announced the invoice of an order for the 12 th and last system arranged to be built in the Business’s initial production run of its advanced BaroShear ™ K45 processing system. Based upon the Business’s exclusive Ultra Shear Technology ™ (UST ™) platform, the BaroShear K45 is a distinct and effective nanoemulsification system created to resolve among the most crucial issues dealing with the worldwide hemp-derived cannabinoid market today: how to make hemp-derived cannabinoid oil successfully soluble in water, to optimize absorption and bioavailability when taken in or applied. The cannabidiol market is predicted to exceed $20 B by 2024 ( Forbes, May 2019).
Low or commonly varying levels of hemp-derived cannabinoid absorption and biological ease of access is a vital issue that may significantly affect the bioavailability and effectiveness of the prospective advantages of hemp-derived cannabinoid products on the market today.
The Business previously announced prepare for its very first production run of twelve (12) BaroShear K45 processing systems with approximated completion times during the 4th quarter of2020 Due to inefficiencies caused by the COVID-19 pandemic, the Business now thinks that all 12 systems will be completed in time for shipment and setup to occur during the very first quarter of2021
Mr. Kenneth F. Micciche, Director of PBI’s UST Program, stated: “The order for the last readily available BaroShear K45 system from our initial production run was received from an exciting young business out of Massachusetts called Canopy CBD Farms, LLC. They use just the highest quality hemp biomass available and the latest processing technologies to satisfy or exceed industry requirements.
Mr. John Westlake, Founder and President of Canopy CBD Farms, LLC., commented: “Scientific data highly supports the critical understanding that hemp-derived cannabinoid oil requires to be processed into an efficiently water-soluble, long-term steady nanoemulsion to achieve the highest quality hemp-derived cannabinoid items possible.
Mr. Richard T. Schumacher, President and CEO of PBI, commented: “We are extremely gratified and thrilled that the preliminary production run of our BaroShear K45 processing systems has sold out.
Mr. Schumacher continued: “Much development has been made in the development of this very unique and ingenious nanoemulsification processing system. Upon their approval, we expect to deliver and install all 12 BaroShear K45 systems throughout Q1 2021, at which point we will recognize approximately $ 2.4 million in earnings.
About Canopy CBD Farms, LLC.
Canopy CBD Farms is a state certified Massachusetts hemp processor and making company. Anticipating the future of government guidelines, we are strategically aligning ourselves with established FDA registered laboratories and makers to bring the greatest of standards and quality of hemp-derived CBD items. Canopy CBD farms serves pharmaceutical and medical research study companies, wishing to establish white label/co-branded manufacturing collaborations with cGMP, GLP makers. Our partnerships will increase wholesale and retail circulation channels, with a ready to identify line of high quality, merchandisable hemp-derived CBD products, for a range of uses and industries.
About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the advancement and sale of innovative, broadly enabling, pressure-based services for the worldwide life sciences and other markets. Additionally, major brand-new market opportunities have actually emerged in the use of our pressure-based technologies in the following locations: (1) the usage of our recently gotten, trademarked innovation from BaroFold, Inc. (the “BaroFold” innovation) to enable entry into the bio-pharma contract services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (” UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or space temperature level steady low-acid liquid foods that can not be efficiently maintained utilizing existing non-thermal innovations.
Forward Looking Statements
This press release contains forward-looking statements. These declarations relate to future occasions or our future financial performance and involve recognized and unidentified threats, uncertainties and other factors that may cause our or our market’s actual outcomes, levels of activity, performance or achievements to be materially different from any future outcomes, levels of activity, efficiency or accomplishments revealed, indicated or presumed by these forward-looking declarations. Sometimes, you can identify forward-looking declarations by terminology such as “may,” “will,” “should,” “could,” “would,” “anticipates,” “strategies,” “plans,” “anticipates,” “believes,” estimates,” “predicts,” “jobs,” “possible” or “continue” or the negative of such terms and other similar terminology. These declarations are only forecasts based upon our present expectations and projections about future occasions. You should not position undue reliance on these declarations. In examining these statements, you must particularly think about various aspects. Actual events or outcomes might vary materially. These and other factors may cause our actual results to vary materially from any forward-looking statement. These risks, uncertainties, and other elements consist of, however are not restricted to, the threats and uncertainties talked about under the heading “Danger Aspects” in the Business’s Annual Report on Type 10- K for the year ended December 31, 2018, and other reports submitted by the Company from time to time with the SEC. The Company carries out no commitment to upgrade any of the information consisted of in this release, other than as otherwise needed by law. Due to rounding, numbers presented throughout this and other documents might not build up exactly to the overalls supplied and percentages might not precisely reflect the absolute figures.
For additional information about PBI and this news release, please click the following site link:
Please visit us on Facebook, LinkedIn, and Twitter.
Richard T. Schumacher, President and CEO
Kenneth F. Micciche, Director– UST Program
SOURCE Pressure BioSciences, Inc.